First-in-human studies are limited to patients with serious diseases for which no curative therapies are available to ensure that the benefits outweigh the risks. However, many patients receive medications that are either victims or perpetrators of drug-drug interactions as part of standard of care. This commentary discusses the current challenges and approaches to safely develop these drugs in patients that require concomitant medications that are potentially either victims or perpetrators of drug-drug interactions.